🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesArterial stiffness reduction on GLP-1 — 6 month update Page 2

Arterial stiffness reduction on GLP-1 — 6 month update

CarlaRPh_TPA Sat, Dec 28, 2024 at 11:25 PM 15 replies 1,728 viewsPage 2 of 3
DanielChem_CHI
Senior Member
1,234
5,678
Mar 2024
Chicago, IL
Dec 29, 2024 at 5:32 PM#6
DebRD_ATL said:
Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history.

This is where I part company with the consensus forming above. The "earlier than weight loss explains" argument is weaker than this thread makes it sound. Blood pressure and inflammatory markers move fast and are downstream of early weight loss, so the mechanism is not as cleanly separable as the summaries imply.

19 22fiona_VT, denise_HTX, raj_cambridge and 16 others
Reply Quote Save Share Report
BiostatsBrad
Member
456
2,345
Jul 2024
Durham, NC
Dec 30, 2024 at 12:43 AM#7
CarlaRPh_TPA said:
My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

From SELECT trial: MACE at 39 months — 6.5% semaglutide vs 8.0% placebo. ARR = 1.5%. NNT = 67 over 3.3 years.

Compare to established therapies:

InterventionNNTTimeframe
Semaglutide (MACE)673.3 years
Statins primary prevention (MI)~1005 years
Aspirin secondary prevention~772 years

These NNTs are clinically meaningful and comparable to accepted cardiovascular interventions.

20 23Dr.BariatricHTX, LindaRN_retired, tommy_boulder and 17 others
Reply Quote Save Share Report
andrew_nyc
Member
534
2,345
Apr 2024
New York, NY
Dec 30, 2024 at 7:54 AM#8
DanielChem_CHI said:
The "earlier than weight loss explains" argument is weaker than this thread makes it sound.

Lp(a) and cardiovascular risk: a nuance that matters. Unlike most lipid markers, Lp(a) is 90%+ genetically determined and doesn't really change with weight loss or GLP-1 therapy.

My Lp(a) has remained at 41 nmol/L across all time points. If yours is elevated (>50 nmol/L), you need additional risk mitigation strategies regardless of your GLP-1 response. Don't assume your medication is covering all cardiovascular risk factors.

Last edited: Dec 30, 2024 at 12:54 PM
21 24PharmD_Rodriguez, julia.endo, JessicaM_2024 and 18 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
sean_dublin
Member
212
890
Nov 2024
Dublin, IE
Dec 30, 2024 at 3:05 PM#9

A narrower follow-up, since the general answer is now clear:

Did your prescriber agree with that reading, and if not what was their objection?

Last edited: Dec 30, 2024 at 4:05 PM
22 0NurseLeah_Nash, gary_naperville, sean_dublin and 19 others
Reply Quote Save Share Report
CarlaRPh_TPA
Senior Member
1,890
8,234
Jan 2024
Tampa, FL
Jan 1, 2025 at 1:31 AM#10
andrew_nyc said:
Lp(a) and cardiovascular risk: a nuance that matters.

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 3 of 5 diagnostic criteria to meeting ZERO after 14 months of treatment.

The 5 criteria (and my journey):

  1. Waist circumference: 53" → 35" ✅ Resolved
  2. Triglycerides: 261 → 96 ✅ Resolved
  3. HDL: 37 → 53 ✅ Resolved
  4. Blood pressure: 141/95 → 119/73 ✅ Resolved
  5. Fasting glucose: 126 → 89 ✅ Resolved

Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.

Last edited: Jan 1, 2025 at 5:31 AM
22 20emily_PDX, Dr.SleepRoch, laura_annarbor and 19 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register